Vijay Pande, founding investor of venture capitalist company Andreessen Horowitz’s Bio + Health fund, discusses advances in biopharmaceutical merger and acquisition (M&A) activity, gene editing, and artificial intelligence (AI) applications in life sciences. He suggests AI shows promise in unlocking the complexities of human disease biology, potentially enhancing the success rate of clinical trials and thereby lowering costs and speeding up drug development. Pande also indicates that M&A activity is expected to surge in 2024.
Beyond Compliance – How VPs of Security Drive Strategic Cybersecurity Initiatives
Modern VPs of Security are evolving from compliance enforcers to strategic leaders, aligning cybersecurity with business goals. They prioritize proactive risk management, adopt Zero Trust
